Allergan Reports Federal Circuit Court of Appeals Ruling.

Business Editors/Health/Medical Writers

IRVINE, Calif.--(BUSINESS WIRE)--March 28, 2003

Allergan, Inc. (NYSE:AGN) announced today that the United States Court of Appeals for the Federal Circuit upheld district court orders granting motions for summary judgment by Alcon and Bausch & Lomb in Allergan's lawsuit alleging infringement of certain Allergan method of use patents relating to Alphagan(R) (brimonidine tartrate ophthalmic solution) 0.2%. The case concerned proposed generic versions of Alphagan(R), which Allergan voluntarily withdrew from U.S. distribution in August 2002.

This ruling does not involve and has no effect on the timing of generic versions of Alphagan(R) P (brimonidine tartrate ophthalmic solution) 0.15%, Allergan's next-generation Alphagan(R) product that has an equivalent efficacy to the original Alphagan(R) product, but with a lower effective dose and a lower incidence of adverse events than the original Alphagan(R) product.

Forward-Looking Statements

This press release contains "forward-looking statements," including, but not limited to, statements regarding the effect of the court's ruling on the approval of generic versions of Alphagan(R) and Alphagan(R) P and the timing of FDA approval for generic versions of the Company's products. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, the uncertainties associated with the litigation and appeal process; the uncertainties regarding the regulatory approval process and the timing associated therewith; potential legislative changes and health care reforms; trends toward managed care and health care cost containment; and other governmental laws and regulations affecting domestic and foreign operations. The reader is thus cautioned not to rely on these forward-looking statements. Additional information concerning these and other risk factors can be found in press releases issued by Allergan as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Certain Factors and Trends Affecting Allergan and its Businesses" in Allergan's Form 10-K for the year ended December 31, 2002. Copies of Allergan's press releases and additional information about Allergan are available on the World Wide Web at www.allergan.com, or you can contact the Allergan Investor Relations Department by calling 714/246-4636.

About Allergan

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator and skin care markets that deliver value to our customers, satisfy unmet medical needs, and improve patients' lives.